Related references
Note: Only part of the references are listed.Current management of newly diagnosed acute promyelocytic leukemia
L. Cicconi et al.
ANNALS OF ONCOLOGY (2016)
All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo
Hayley S. Ma et al.
BLOOD (2016)
All-trans retinoic acids induce differentiation and sensitize a radioresistant breast cancer cells to chemotherapy
Yunwen Yan et al.
BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE (2016)
All-trans retinoic acid targets gastric cancer stem cells and inhibits patient-derived gastric carcinoma tumor growth
P. H. Nguyen et al.
ONCOGENE (2016)
Cancer stem cells and chemoresistance: The smartest survives the raid
Jihe Zhao
PHARMACOLOGY & THERAPEUTICS (2016)
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide
David Sanford et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Aldehyde Dehydrogenase Is Regulated by β-Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells
Monica Cojoc et al.
CANCER RESEARCH (2015)
All-trans retinoic acid downregulates ALDH1-mediated stemness and inhibits tumour formation in ovarian cancer cells
Ming-Jer Young et al.
CARCINOGENESIS (2015)
Cancer stem-like cells of ovarian clear cell carcinoma are enriched in the ALDH-high population associated with an accelerated scavenging system in reactive oxygen species
T. Mizuno et al.
GYNECOLOGIC ONCOLOGY (2015)
Combination Treatment with All-Trans Retinoic Acid Prevents Cisplatin-Induced Enrichment of CD133+ Tumor-Initiating Cells and Reveals Heterogeneity of Cancer Stem Cell Compartment in Lung Cancer
Massimo Moro et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Vitamin A, Cancer Treatment and Prevention: The New Role of Cellular Retinol Binding Proteins
Elena Doldo et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Cancer stem-like cells from head and neck cancers are chemosensitized by the Wnt antagonist, sFRP4, by inducing apoptosis, decreasing stemness, drug resistance and epithelial to mesenchymal transition
S. Warrier et al.
CANCER GENE THERAPY (2014)
Aldehyde dehydrogenases in cancer: an opporunity for biomaker and drug development?
Klaus Pors et al.
DRUG DISCOVERY TODAY (2014)
Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML
Giridharan Ramsingh et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2014)
Tamibarotene As Maintenance Therapy for Acute Promyelocytic Leukemia: Results From a Randomized Controlled Trial
Katsuji Shinagawa et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Targeting Head and Neck Cancer Stem Cells to Overcome Resistance to Photon and Carbon Ion Radiation
Gerald Bertrand et al.
STEM CELL REVIEWS AND REPORTS (2014)
The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance
Radoslaw Januchowski et al.
BIOMEDICINE & PHARMACOTHERAPY (2013)
Enzymology of retinoic acid biosynthesis and degradation
Natalia Y. Kedishvili
JOURNAL OF LIPID RESEARCH (2013)
Reversing the Intractable Nature of Pancreatic Cancer by Selectively Targeting ALDH-High, Therapy-Resistant Cancer Cells
Sang Kyum Kim et al.
PLOS ONE (2013)
Retinoids in Pediatric Onco-Hematology: the Model of Acute Promyelocytic Leukemia and Neuroblastoma
Riccardo Masetti et al.
ADVANCES IN THERAPY (2012)
Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44+ human breast cancer cells
Alysha K. Croker et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
The enzymatic activity of human aldehyde dehydrogenases 1A2 and 2 (ALDH1A2 and ALDH2) is detected by Aldefluor, inhibited by diethylaminobenzaldehyde and has significant effects on cell proliferation and drug resistance
Jan S. Moreb et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2012)
The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells
Jenny M. Whitworth et al.
GYNECOLOGIC ONCOLOGY (2012)
Vitamin A: History, Current Uses, and Controversies
M. Shane Chapman
SEMINARS IN CUTANEOUS MEDICINE AND SURGERY (2012)
Concise Review: Cancer Stem Cells and Minimal Residual Disease
Gabriel Ghiaur et al.
STEM CELLS (2012)
Aldehyde Dehydrogenase Inhibitors: a Comprehensive Review of the Pharmacology, Mechanism of Action, Substrate Specificity, and Clinical Application
Vindhya Koppaka et al.
PHARMACOLOGICAL REVIEWS (2012)
Retinoids, Retinoic Acid Receptors, and Cancer
Xiao-Han Tang et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 6 (2011)
Retinoic Acid Enhances TRAIL-Induced Apoptosis in Cancer Cells by Upregulating TRAIL Receptor 1 Expression
Latha Dhandapani et al.
CANCER RESEARCH (2011)
Aldehyde Dehydrogenase in Combination with CD133 Defines Angiogenic Ovarian Cancer Stem Cells That Portend Poor Patient Survival
Ines A. Silva et al.
CANCER RESEARCH (2011)
A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer
Margarette Bryan et al.
INVESTIGATIONAL NEW DRUGS (2011)
The Role of Human Aldehyde Dehydrogenase in Normal and Cancer Stem Cells
Irene Ma et al.
STEM CELL REVIEWS AND REPORTS (2011)
The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases
Sandeep Tyagi et al.
JOURNAL OF ADVANCED PHARMACEUTICAL TECHNOLOGY & RESEARCH (2011)
Retinoid pathway and cancer therapeutics
Nathan Bushue et al.
ADVANCED DRUG DELIVERY REVIEWS (2010)
The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA
Alan K. Burnett et al.
BLOOD (2010)
In vitro treatment with retinoids decreases bcl-2 protein expression and enhances dexamethasone-induced cytotoxicity and apoptosis in multiple myeloma cells
Patrizia Tosi et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Randomized Phase II Trial of All-Trans-Retinoic Acid With Chemotherapy Based on Paclitaxel and Cisplatin As First-Line Treatment in Patients With Advanced Non-Small-Cell Lung Cancer
Oscar Arrieta et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma.
Alice L. Yu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome
Emmanuel Raffoux et al.
ONCOTARGET (2010)
Aldehyde dehydrogenase activity as a functional marker for lung cancer
Deniz Ucar et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2009)
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance
William Matsui et al.
CANCER RESEARCH (2008)
Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily
Satori A. Marchitti et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2008)
Aldehyde Dehydrogenase as a Marker for Stem Cells
Jan S. Moreb
CURRENT STEM CELL RESEARCH & THERAPY (2008)
Diverse actions of retinoid receptors in cancer prevention and treatment
Nigel P. Mongan et al.
DIFFERENTIATION (2007)
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome
Christophe Ginestier et al.
CELL STEM CELL (2007)
Heterogeneity of aldehyde dehydrogenase expression in lung cancer cell lines is revealed by aldefluor flow cytometry-based assay
Jan S. Moreb et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2007)
Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential
A. M. S. Cheung et al.
LEUKEMIA (2007)
Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells
Maxy De los Santos et al.
MOLECULAR CANCER THERAPEUTICS (2007)
RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide
Jan S. Moreb et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
International Union of Pharmacology. LX. Retinoic acid receptors
Pierre Germain et al.
PHARMACOLOGICAL REVIEWS (2006)
Retinoic acid down-regulates aldehyde dehydrogenase and increases cytotoxicity of 4-hydroperoxycyclophosphamide and acetaldehyde
JS Moreb et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Retinoid therapy of high-risk neuroblastoma
CP Reynolds et al.
CANCER LETTERS (2003)
Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: Results of the phase III clinical trial
P Heald et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2003)
Human aldehyde dehydrogenases: Potential pathological, pharmacological, and toxicological impact
NE Sladek
JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY (2003)
Stem cells, cancer, and cancer stem cells
T Reya et al.
NATURE (2001)
Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational phase II-III trial results
M Duvic et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
A combination treatment of c-myc antisense DNA with all-trans-retinoic acid inhibits cell proliferation by downregulating c-myc expression in small cell lung cancer
K Akie et al.
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT (2000)
Interferon-α and 13-cis-retinoic acid as maintenance therapy after high-dose combination chemotherapy with growth factor support for small cell lung cancer -: a feasibility study
T Ruotsalainen et al.
ANTI-CANCER DRUGS (2000)